


Isolation of a highly-purified HSC-enriched CD34⁺CD90⁺CD45RA⁻ cell subset for allogeneic transplantation in the nonhuman primate large-animal model


Classical CD34-mediated Allo-HCT



Limitations:

- Unpredictable Transplant Success
- Low Targeting Efficiency of HSCs for Allo-HCT + Gene Therapy


NEW CD90-mediated Allo-HCT



Advantages:


- Depletion of T cell Progenitors
- Predictable Recovery Onset and Success
- Refined Target for Allo-HCT + Gene Therapy

Proof-of-concept study in NHPs



Conclusions:

- CD90 Purification Feasible
- No Impact on Engraftment
- Rapid BM HSPC Recovery
- High Levels of Chimerism



Allo-HCT: Allogeneic Hematopoietic Cell Transplant; HSPC: Hematopoietic Stem and Progenitor Cells; HSC: Hematopoietic Stem Cell; NHP: Nonhuman Primate; BM: Bone Marrow

Radtke et al. *Transplantation Direct*. August 2020

@TransplantJrnl

Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved